Published in Sleep on February 01, 2009
XP13512 (GSK1838262) Versus Placebo in Patients With Restless Legs Syndrome. | NCT00298623
Algorithms for the diagnosis and treatment of restless legs syndrome in primary care. BMC Neurol (2011) 1.32
Strategies for the treatment of restless legs syndrome. Neurotherapeutics (2012) 1.03
A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome. J Clin Sleep Med (2011) 0.93
Review: management of Parkinson's disease. Neuropsychiatr Dis Treat (2013) 0.93
Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled study. Mayo Clin Proc (2010) 0.92
Restless legs syndrome-current therapies and management of augmentation. Nat Rev Neurol (2015) 0.86
The use of gabapentin enacarbil in the treatment of restless legs syndrome. Ther Adv Neurol Disord (2010) 0.81
Gabapentin enacarbil - clinical efficacy in restless legs syndrome. Neuropsychiatr Dis Treat (2010) 0.81
Review of the treatment of restless legs syndrome: focus on gabapentin enacarbil. J Cent Nerv Syst Dis (2012) 0.75
Parkinson disease: an update. Neurologist (2004) 0.75
Gabapentin enacarbil: pharmacotherapy of restless legs syndrome. J Cent Nerv Syst Dis (2010) 0.75
Practice guideline summary: Treatment of restless legs syndrome in adults: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology (2016) 0.75
Role of gabapentin enacarbil XR in restless legs syndrome. Ther Clin Risk Manag (2012) 0.75
Efficacy and Tolerability of Gabapentin in Adults with Sleep Disturbance in Medical Illness: A Systematic Review and Meta-analysis. Front Neurol (2017) 0.75
Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med (2003) 12.71
Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA (1998) 5.16
Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med (2005) 4.97
Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med (2003) 4.95
Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain (2001) 2.98
Efficacy and safety of pramipexole in restless legs syndrome. Neurology (2006) 2.63
Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology (2002) 2.53
Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep (2004) 1.87
Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med (2004) 1.79
Restless legs syndrome: a community-based study of prevalence, severity, and risk factors. Neurology (2005) 1.77
Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry (2004) 1.52
Evaluating the quality of life of patients with restless legs syndrome. Clin Ther (2004) 1.44
Restless legs syndrome symptoms in primary care: a prevalence study. Arch Intern Med (2003) 1.27
Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study--the PRELUDE study. Sleep Med (2006) 1.27
Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord (2004) 1.26
Immobilization tests and periodic leg movements in sleep for the diagnosis of restless leg syndrome. Mov Disord (1998) 1.22
Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome. Neuropsychobiology (2003) 1.16
Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. The International Gabapentin Study Group. Epilepsia (1994) 1.12
XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol Exp Ther (2004) 1.10
Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability. Epilepsy Res (2000) 1.09
Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. J Clin Pharmacol (2008) 1.06
Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 1. Findings on objective and subjective sleep and awakening quality. Neuropsychobiology (2000) 1.04
Gabapentin increases slow-wave sleep in normal adults. Epilepsia (2002) 0.99
Acute placebo-controlled sleep laboratory studies and clinical follow-up with pramipexole in restless legs syndrome. Eur Arch Psychiatry Clin Neurosci (2002) 0.96
Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome. Sleep Med (2005) 0.95
Gabapentin versus levodopa for the treatment of Restless Legs Syndrome in hemodialysis patients: an open-label study. Ren Fail (2004) 0.95
Treatment of idiopathic restless legs syndrome (RLS) with gabapentin. Neurology (2001) 0.93
Long-term treatment of restless legs syndrome with dopamine agonists. Arch Neurol (2004) 0.93
Ropinirole for restless legs syndrome: a placebo-controlled crossover trial. Neurology (2004) 0.90
A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients. Am J Kidney Dis (2001) 0.90
Successful treatment of reflex sympathetic dystrophy with gabapentin. Am J Emerg Med (1995) 0.90
Management of restless legs syndrome with gabapentin (Neurontin) Sleep (1996) 0.86
Treatment of restless legs syndrome with gabapentin. Clin Neuropharmacol (1997) 0.83
Gabapentin in the management of convulsive disorders. Epilepsia (1999) 0.82
Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med (2003) 12.71
Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med (2005) 4.97
History of the development of sleep medicine in the United States. J Clin Sleep Med (2005) 4.22
Shift work sleep disorder: prevalence and consequences beyond that of symptomatic day workers. Sleep (2004) 3.78
Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med (2004) 3.49
Sleep loss and REM sleep loss are hyperalgesic. Sleep (2006) 3.03
Place of chronic insomnia in the course of depressive and anxiety disorders. J Psychiatr Res (2002) 2.99
Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry (2006) 2.86
The association of insomnia with anxiety disorders and depression: exploration of the direction of risk. J Psychiatr Res (2006) 2.60
Modafinil for excessive sleepiness associated with shift-work sleep disorder. N Engl J Med (2005) 2.51
Prevalence of restless legs syndrome and periodic limb movement disorder in the general population. J Psychosom Res (2002) 2.48
Early CPAP use identifies subsequent adherence to CPAP therapy. Sleep (2007) 2.19
Sleep in lifetime posttraumatic stress disorder: a community-based polysomnographic study. Arch Gen Psychiatry (2004) 2.13
Restless legs syndrome: prevalence and impact in children and adolescents--the Peds REST study. Pediatrics (2007) 2.07
Epidemiology of DSM-IV insomnia in adolescence: lifetime prevalence, chronicity, and an emergent gender difference. Pediatrics (2006) 2.06
The association between obesity and short sleep duration: a population-based study. J Clin Sleep Med (2005) 1.87
The pediatric daytime sleepiness scale (PDSS): sleep habits and school outcomes in middle-school children. Sleep (2003) 1.86
Vulnerability to stress-related sleep disturbance and hyperarousal. Sleep (2004) 1.84
Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology (2012) 1.83
Enhanced external counter pulsation (EECP) as a novel treatment for restless legs syndrome (RLS): a preliminary test of the vascular neurologic hypothesis for RLS. Sleep Med (2005) 1.82
Insomnia and the performance of US workers: results from the America insomnia survey. Sleep (2011) 1.77
Sleep, sleepiness, sleep disorders and alcohol use and abuse. Sleep Med Rev (2001) 1.75
Prevalence, demographics, and psychological associations of sleep disruption in patients with cancer: University of Rochester Cancer Center-Community Clinical Oncology Program. J Clin Oncol (2009) 1.73
Using difficulty resuming sleep to define nocturnal awakenings. Sleep Med (2010) 1.73
Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep (2007) 1.72
Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet (2008) 1.72
The scoring of arousal in sleep: reliability, validity, and alternatives. J Clin Sleep Med (2007) 1.71
Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis Rheum (2009) 1.70
Half of patients with obstructive sleep apnea have a higher NREM AHI than REM AHI. Sleep Med (2006) 1.66
Crohn's disease is associated with restless legs syndrome. Inflamm Bowel Dis (2010) 1.66
Rise of blood pressure with periodic limb movements in sleep and wakefulness. Clin Neurophysiol (2007) 1.62
Insomnia causes, consequences, and therapeutics: an overview. Depress Anxiety (2003) 1.54
Efficacy and safety of zolpidem extended release in elderly primary insomnia patients. Am J Geriatr Psychiatry (2008) 1.51
Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial. Am J Gastroenterol (2005) 1.48
Celiac disease is associated with restless legs syndrome. Dig Dis Sci (2010) 1.47
The restless legs syndrome. Lancet Neurol (2005) 1.46
Patient-reported outcomes in insomnia: development of a conceptual framework and endpoint model. Behav Sleep Med (2013) 1.43
Caffeine: sleep and daytime sleepiness. Sleep Med Rev (2007) 1.41
Armodafinil for treatment of excessive sleepiness associated with shift work disorder: a randomized controlled study. Mayo Clin Proc (2009) 1.38
RLS in middle aged women and attention deficit/hyperactivity disorder in their offspring. Sleep Med (2011) 1.38
Sleep during titration predicts continuous positive airway pressure compliance. Sleep (2003) 1.37
Sleep and pain: interaction of two vital functions. Semin Neurol (2005) 1.37
Prevalence and polysomnographic correlates of insomnia comorbid with medical disorders. Sleep (2011) 1.35
Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord (2008) 1.33
Prospective study of restless legs syndrome and coronary heart disease among women. Circulation (2012) 1.29
Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin (2004) 1.29
The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin (2006) 1.28
Sleep hygiene practices in a population-based sample of insomniacs. Sleep (2005) 1.26
The 10-year risk of verified motor vehicle crashes in relation to physiologic sleepiness. Sleep (2010) 1.25
Standard operation procedures for conducting the on-the-road driving test, and measurement of the standard deviation of lateral position (SDLP). Int J Gen Med (2011) 1.24
Definition of restless legs syndrome, how to diagnose it, and how to differentiate it from RLS mimics. Mov Disord (2007) 1.21
Traditional Chinese medicine herbal preparations in restless legs syndrome (RLS) treatment: a review and probable first description of RLS in 1529. Sleep Med Rev (2012) 1.20
Nighttime insomnia symptoms and perceived health in the America Insomnia Survey (AIS). Sleep (2011) 1.19
Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med (2007) 1.17
Ethanol and sleep loss: a "dose" comparison of impairing effects. Sleep (2003) 1.17
The prevalence of multiple sleep-onset REM periods in a population-based sample. Sleep (2006) 1.17
Pharmacologic management of insomnia in children and adolescents: consensus statement. Pediatrics (2006) 1.16
Gender differences in pharmacokinetics and pharmacodynamics of zolpidem following sublingual administration. J Clin Pharmacol (2013) 1.16
Restless legs syndrome: a comprehensive overview on its epidemiology, risk factors, and treatment. Sleep Breath (2011) 1.16
Shift work sleep disorder: burden of illness and approaches to management. Drugs (2006) 1.15
Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch Gen Psychiatry (2008) 1.15
Zolpidem for insomnia. Expert Opin Pharmacother (2012) 1.14
Periodic limb movements during sleep: population prevalence, clinical correlates, and racial differences. Sleep (2008) 1.13
MSLT in primary insomnia: stability and relation to nocturnal sleep. Sleep (2011) 1.13
Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial. J Clin Psychiatry (2010) 1.13
Sleep disturbance in psychiatric disorders: effects on function and quality of life in mood disorders, alcoholism, and schizophrenia. Ann Clin Psychiatry (2008) 1.12
Evidence continues to mount on the relationship of restless legs syndrome/ periodic limb movements in sleep to hypertension, cardiovascular disease, and stroke. Sleep (2010) 1.12
XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol Exp Ther (2004) 1.10
Restless legs syndrome--theoretical roles of inflammatory and immune mechanisms. Sleep Med Rev (2012) 1.09
Tolerance to daytime sedative effects of H1 antihistamines. J Clin Psychopharmacol (2002) 1.09
Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial. Obstet Gynecol (2006) 1.09
The Johns Hopkins telephone diagnostic interview for the restless legs syndrome: preliminary investigation for validation in a multi-center patient and control population. Sleep Med (2003) 1.08
Reliability and validity of the brief insomnia questionnaire in the America insomnia survey. Sleep (2010) 1.08
Symptoms of attention-deficit/hyperactivity disorder in adults with restless legs syndrome. Sleep (2004) 1.07
The associations of insomnia with costly workplace accidents and errors: results from the America Insomnia Survey. Arch Gen Psychiatry (2012) 1.07
Consequences of shiftworking on sleep duration, sleepiness, and sleep attacks. Chronobiol Int (2010) 1.07
Stress-related sleep disturbance and polysomnographic response to caffeine. Sleep Med (2006) 1.06
The relationship among restless legs syndrome (Willis-Ekbom Disease), hypertension, cardiovascular disease, and cerebrovascular disease. J Neurol (2013) 1.05
Insomnia pharmacotherapy. Neurotherapeutics (2012) 1.05
Tiagabine is associated with sustained attention during sleep restriction: evidence for the value of slow-wave sleep enhancement? Sleep (2006) 1.04
XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J Pharmacol Exp Ther (2004) 1.03
Sleep reactivity and insomnia: genetic and environmental influences. Sleep (2011) 1.03
Nocturnal rapid eye movement sleep latency for identifying patients with narcolepsy/hypocretin deficiency. JAMA Neurol (2013) 1.02
Pain sensitivity in sleepy pain-free normals. Sleep (2009) 1.02
Safety of ramelteon in individuals with mild to moderate obstructive sleep apnea. Sleep Breath (2007) 1.02
The reliability, validity and responsiveness of the International Restless Legs Syndrome Study Group rating scale and subscales in a clinical-trial setting. Sleep Med (2006) 1.02
Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression. J Clin Sleep Med (2007) 1.01
Neurophysiology of sleep and wakefulness: basic science and clinical implications. Curr Neuropharmacol (2008) 1.01
Some children with growing pains may actually have restless legs syndrome. Sleep (2004) 1.01
Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol (2011) 1.01
The venom composition of the parasitic wasp Chelonus inanitus resolved by combined expressed sequence tags analysis and proteomic approach. BMC Genomics (2010) 1.00
Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry (2008) 0.99
Pain sensitivity and recovery from mild chronic sleep loss. Sleep (2012) 0.99
Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia. Sleep (2011) 0.99
Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States. Mov Disord (2010) 0.98
Restless legs syndrome: confirmation of linkage to chromosome 12q, genetic heterogeneity, and evidence of complexity. Arch Neurol (2005) 0.98
Efficacy and Safety of Doxepin 1 mg and 3 mg in a 12-week Sleep Laboratory and Outpatient Trial of Elderly Subjects with Chronic Primary Insomnia. Sleep (2010) 0.97